Closing patent foramen ovale in cryptogenic stroke: The underscored importance of other interatrial shunt variants

Gianluca Rigatelli, Alberto Rigatelli

Gianluca Rigatelli, Section of Adult Congenital and Adult Heart Disease, Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, 45100 Rovigo, Italy
Alberto Rigatelli, Urgency Medicine, Verona University Medical School, 37045 Verona, Italy

Author contributions: Rigatelli G designed research; Rigatelli G and Rigatelli A performed research; Rigatelli A contributed new reagents or analytic tools; Rigatelli G wrote the paper.

Conflict-of-interest: None of the authors has conflict of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Gianluca Rigatelli, MD, PhD, Section of Adult Congenital and Adult Heart Disease, Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Viale Tre martiri, 45100 Rovigo, Italy. jackyheart71@yahoo.it
Telephone: +39-347-1912016
Fax: +39-425-394513

Received: January 29, 2015
Peer-review started: January 29, 2015
First decision: March 6, 2015
Revised: March 13, 2015
Accepted: April 16, 2015
Article in press: April 20, 2015
Published online: June 26, 2015

Abstract
Recent trials and metanalysis even not fully conclusive and still debated, at least suggested that mechanical device-based closure of patent foramen ovale (PFO) is more effective than medical therapy in prevent recurrence of stroke. In a proportion ranging from 20% to nearly 40% of patients in literature, PFO is associated to atrial septal aneurysm (ASA): ASA is a well-known entity often associated with additional fenestration. Additionally small atrial septal defects ("Flat ASD") can present with signs of paradoxical embolism and cannot be easily detected by transthoracic echocardiography or even by transesophageal echocardiography and are usually discovered by intracardiac echocardiography at the moment of transcatheter closure. This evidence might change potentially the anatomical diagnosis from PFO to fenestrated ASA or as we called it to “hybrid defect”, being a bidirectional flow through a small ASD or/and an additional fenestration, often present. Despite the differences in anatomy, pathophysiology and haemodynamic paradoxical embolism may occur in both entities and also may be the first appearance of fenestrated ASA. Because some overlapping do really exist between PFO and hybrid defects, which are often not clearly differentiable by standard diagnostic tools, it is likely that a proportion of patients evaluated for potential transcatheter closure of PFO had actually a different anatomical substrate. These different anatomical and pathophysiologic entities have not been address in any of the previous trials, potentially having an impact on overall results despite the similar mechanical treatment. Neurologists and general cardiologists in charge of clinical management of PFO-related cryptogenic stroke should be aware of the role of hybrid defects in the pathophysiology of paradoxical embolism - mediated cerebral ischemic events in order to apply the correct decision - making process and avoid downgrading of patients with paradoxical embolism-related interatrial shunt variants different from PFO.

Key words: Atrial septal defect; Patent foramen ovale; Echocardiography; Anatomy
INTRODUCTION

Recent trials and meta-analysis and in particular, the RESPECT trial\(^1\), even not fully conclusive and still debated, at least suggested that mechanical device-based closure of patent foramen ovale (PFO) is more effective in prevent recurrence of stroke by near 67%. When looking deeply into the number of different metaanalysis of PFO closure for cryptogenic (or better paradoxical embolism mediated) stroke\(^2\)\(^-\)\(^7\), it appears clear that in a proportion ranging from 20% to nearly 40% of patients PFO is associated to atrial septal aneurysm (ASA): ASA is a well-known entity often associated with additional fenestration\(^8\). Additionally small atrial septal defects can present with signs of paradoxical embolism and cannot be easily detected by transthoracic echocardiography or even by transesophageal echocardiography and are usually discovered by intracardiac echocardiography at the moment of transcatheter closure\(^9\), confusing even more the diagnosis of PFO which is at the basis of all the studies about effectiveness of transcatheter closure in cryptogenic stroke. This evidence might change potentially the anatomical diagnosis from PFO to fenestrated ASA (or fenestrated secundum atrial septal defect) or to a so called "hybrid defect", [a small single atrial septal defects (ASD) associated with paradoxical embolism], being a bidirectional flow through a small ASD or and additional fenestration often present. The aim of this review is to analyse conjunction points between PFOs and hybrid defects and outlined the role of these type of interatrial shunt in the pathophysiology of paradoxical embolism.

PRACTICAL EPIDEMIOLOGY

Isolated ASD represent 7% of all cardiac anomalies and can present at any age\(^10\). Adolescents and adults with isolated atrial septal defects are more likely to reach adult age without being diagnosed. Secundum ASD is by far the most common type, occurring in 1/1500 live births, with 65% to 75% involving females\(^10\). On the other hand, PFO represents an endemic variant in the normal population with a prevalence of 25%-27%\(^11\). These two entities appear so different that is difficult to find a conjunction ring: nevertheless we use the same philosophy for the treatment. Indeed, device - based closure has been proved to be effective\(^12\)\(^,\)\(^13\) in both settings.

Anatomy, pathophysiology, and haemodynamic

From an anatomic and pathophysiological point of view these two entities are absolutely different. The ostium secundum ASD is a defect of the atrial septum (Figure 1) within the limit of the fossa ovalis and causes usually a left-to-right shunt, being the left atrial pressure higher than the right atrial one. The volume of and direction of flow through an ASD depend on the size of the hole and the relative diastolic filling properties of the left and right chambers. Reduced left ventricle compliance and mitral stenosis increase the left-to-right shunt, whereas reduced right ventricle compliance may decrease the left-to-right shunt or may cause a right-to-left shunt. A Qp/Qs ratio > 1.5:1 or dilation of the right chambers defined a left-to-right shunt as significant\(^14\).

The PFO is defined as the incompetence of the fossa ovale valve determining a right-to-left shunt (Figure 2). The reason because a right-to-left atrial
shunting occurs with normal intracardiac pressures and normal or near-normal pulmonary function through a PFO has still not been completely clarified. An explanation may arise from some few considerations. Firstly, a physiologic transient spontaneous reversal of difference between the left and the right pressure is physiologically present during early diastole and during isovolumetric contraction of the right ventricle of each cardiac cycle; this right-to-left gradient may be sustained by physiologic manoeuvres that increase the right atrial pressure such as posture, inspiration, cough or Valsalva manoeuvre, or by situation in which pulmonary vascular resistances results increased, such as acute pulmonary embolism, hypoxemia due to obstructive sleep apnoea, severe chronic obstructive pulmonary disease, right ventricular infarction and positive end-expiratory pressure during neurosurgical procedures in the sitting position. Secondly, another theory explaining the right-to-left shunting through a PFO, is represented by the “so-called” “flow phenomenon”. It describes a preferential blood flow from the inferior vena cava towards the atrial septum as a part of the ancient foetal circulation pathway[13].

Thirdly, the increasing stiffness of the right chambers compared to the left chambers caused by aging has been postulated. Finally, conditions such due to mediastinal shift or heart counter-clockwise rotation and/or distortion, following an ascending aorta enlargement, right pneumectomy or pericardial effusion may cause an anatomic disarray of the inferior vena cava relationship with the interatrial septum favouring part of the blood flow to enter the left atrium throughout a PFO[16].

Even from a haemodynamic point of view, ASD obviously differs from PFO. ASD are usually associated with pulmonary hypertension of different degree, an increased Qp/Qs ratio and enlarged right chambers, whereas the usual findings in PFO patients is a normal or slightly elevated pulmonary pressure, normal Qp/Qs ratio, and normal right chambers. Sometimes in presence of a PFO associated with large ASA, a mild impairment of the left atrial function can be observed[17].

Usually also fenestrated secundum ASD with or without ASA tends to present less right chambers enlargement and only slightly increase in mean pulmonary pressure compared to secundum ASD.

**CONJUNCTION POINTS**

Despite the gross differences in anatomy and haemodynamic, when we look to the clinical presentation and patho-physiology, we can find some contact points. Excepted for supraventricular arrhythmias and dyspnœa, usually present only in secundum single and fenestrated ASD, paradoxical embolism may occur in both entities and also may be the first appearance of fenestrated ASD with or without ASA.

Usually paradoxical embolism is associated with PFO but occasionally secundum ASD, pulmonary arterio-venous fistula, and other intracardiac septal defects may act as alternative pathophysiological mechanism. Microemboli from a vein thrombotic location, or as recently postulated[17] microthrombotic stratification on the surface of a huge ASA or in the left atrium itself as a result of a left atrial dysfunction induced by the PFO and ASA itself, may navigate to the left side of the circulation through the PFO causing different ischemic syndromes. Differently, the pathophysiology of paradoxical embolism through a secundum ASD is usually caused by a temporary right heart pressure increasing which induce a right-to-left shunting which allows a venous thromboembolus to enter the arterial circulation. As an alternative mechanism, Valsalva manoeuvre, coughing, or straining might increase right-to-left component of a bidirectional shunt inducing a paradoxical embolism in ASD patients, in particular in elderly patients, more prone to rapid change of right chambers pressure because of the increasing stiffness of the chambers.

Recently in an analysis of our institutional database we found 24 (6.2%) with a secundum ASD out of 386 patients evaluated for paradoxical embolism. Defects were multifenestrated in 41.6% (10/24). Single ASD (58.3%) had a “flat” elliptical shape with a major axis of 7.6 ± 2.4 and minimal axis of 2.5 ± 1.6 mm when assessed with intracardiac echocardiography. Patients with ASD-related paradoxical embolism had more frequently a deep venous thrombosis, bigger stroke areas compared to PFO patients, and massive curtain shunt on Valsalva maneuver on transcranial
Doppler. When compared to non-emboligenous ASD, they had lower mean pulmonary pressure, lower mean Qp/Qs, and had bidirectional shunt at rest\(^{[18]}\). As matter of fact, flat elliptical shape ASD and fenestrated ASD with or without ASA appear to represent the conjunction ring between ASD and PFO, being a hybrid hemodynamic and clinical profile compared to each of the others (Figure 3).

**FINAL CONSIDERATIONS: ARE THE PAST TRIALS REALLY FOCUSED ON THE PROPER ANATOMICAL ENTITY?**

Because some overlapping do really exist between PFO, fenestrated ASD and hybrid defects (Figure 1) which are not always clearly differentiable by standard diagnostic tools, it is likely that a proportion of patients evaluated for potential transcatheter closure of PFO had actually a different anatomical substrate. Past trials and case series used Transesophageal guidance in the majority of patients and the severity of the shunt and presence of permanent shunt has not been evaluated systematically by Transcranial Doppler or transesophageal echocardiography in the enrolment process.

Current modern judgement about medical or mechanical closure is suggested to be based, following the only published multidisciplinary consensus\(^{[19]}\), on recurrent stroke or ischemic event with positive neuroimaging studies, severe shunt graded by transcranial Doppler and transesophageal echocardiography, presence of permanent shunt, and of additional anatomical features, such as ASA, tunnel-like opening, and Eustachian valve. The large and permanent shunt in particular, as previously suggested\(^{[18,20]}\) is one of the most influent parameters, and it appears clear that in presence of an hybrid defect, it doesn't play the same role as in true PFO, while ASA and Eustachian valve may be more influent facilitating paradoxical shunt through an hybrid defect or a fenestrated ASD when a Valsalva manoeuvre is provoked. These different anatomical and pathophysiogetic pictures have not been address in any of the previous trials, potentially having an impact on overall results despite the similar mechanical treatment.

From a practical point of view, patients with deep vein thrombosis and more clinically relevant ischemic syndrome are more likely to have a hybrid defect, whereas patients with no deep vein thrombosis and mild symptomatology are more likely to have a PFO. An ideal screening of a patient with suspected paradoxical embolism should include not only the transthoracic echo, but also the transesophageal echo in order to differentiate between PFO and hybrid defects.

At the light of what we discussed above, neurologists and general cardiologists in charge of clinical management of PFO-related cryptogenic stroke should be aware of the role of hybrid defects and multi-fenestrated ASA in the pathophysiology of paradoxical embolism - mediated cerebral ischemic events in order to apply the correct decision -making process and avoid downgrading of patients with paradoxical embolism-related interatrial shunt variants different from PFO.

**REFERENCES**

1. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL. Closure of patent...
foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med* 2013; 368: 1092-1100 [PMID: 23514286 DOI: 10.1056/NEJMoa1301440]

2. Riaz IB, Dhoble A, Mizyed A, Hsu CH, Husnain M, Lee JZ, Lotan K, Lee KS. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials. *BMC Cardiovasc Disord* 2013; 13: 116 [PMID: 24330204 DOI: 10.1186/1471-2261-13-116]

3. Khan AR, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Teyyeh I, Khuder S, Eltahawy EA. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. *JACC Cardiovasc Interv* 2013; 6: 1316-1323 [PMID: 24139929 DOI: 10.1016/j.jcvi.2013.08.001]

4. Udeli JA, Opotowsky AR, Khairy P, Silversides CK, Gladstone DJ, O’Gara PT, Landzberg MJ. Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses. *Can J Cardiol* 2014; 30: 1216-1224 [PMID: 25154803 DOI: 10.1016/j.cjca.2014.05.004]

5. Pandit A, Aryal MR, Pandit AA, Jalota L, Kantharajpur S, Hakim FA, Lee HR. Amplatzer PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta-analysis of randomised trials. *Heart Lung Circ* 2014; 23: 303-308 [PMID: 24495944 DOI: 10.1016/j.hlc.2013.12.003]

6. Capodanno D, Milazzo G, Vitale L, Di Stefano D, Di Salvo M, Grasso C, Tamburino C. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. *EuroIntervention* 2014; 9: 1342-1349 [PMID: 24240356 DOI: 10.4244/EIJV9I9A225]

7. Rigatelli G, Dell’avvocata F, Vassiliev D, Daggubati R, Buch, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Teyyeh I, Khuder S, Eltahawy EA. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a meta-analysis of randomized clinical trials. *BMC Cardiovasc Disord* 2013; 13: 116 [PMID: 24330204 DOI: 10.1186/1471-2261-13-116]

8. Rigatelli G, Dell’avvocata F, Vassiliev D, Daggubati R, Buch, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Teyyeh I, Khuder S, Eltahawy EA. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a meta-analysis of randomized clinical trials. *BMC Cardiovasc Disord* 2013; 13: 116 [PMID: 24330204 DOI: 10.1186/1471-2261-13-116]

9. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. *Circulation* 2007; 115: 163-172 [PMID: 17210844 DOI: 10.1161/CIRCULATIONAHA.106.627224]

10. Rigatelli G, Rigatelli G. Congenital heart diseases in aged patients: clinical features, diagnosis, and therapeutic indications based on the analysis of a twenty five-year Medline search. *Cardiol Rev* 2005; 13: 293-296 [PMID: 16230886 DOI: 10.1097/01. card.0000145928.08280.ef]

11. Pickett CA, Villines TC, Ferguson MA, Hulten EA. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials. *Tex Heart Inst J* 2014; 41: 357-367 [PMID: 25120387 DOI: 10.14503/THIJ-13-3879]

12. Webb G, Gatzoulis MA. Atrial septal defects in the adult: recent progress and overview. *Circulation* 2006; 114: 1645-1653 [PMID: 17030704 DOI: 10.1161/CIRCULATIONAHA.105.592055]

13. Zanchetta M, Rigatelli G, Ho SY. A mystery featuring right-to-left shunting despite normal intracardiac pressure. *Chest* 2005; 128: 998-1002 [PMID: 16100198 DOI: 10.1378/chest.128.2.998]

14. Kilner PJ, Yang GZ, Wilkes AJ, Mohiaddin RH, Firmin DN, Yacoub MH. Asymmetric redirection of flow through the heart. *Nature* 2000; 404: 759-761 [PMID: 10783888 DOI: 10.1038/35008075]

15. Rigatelli G, Dell’avvocata F, Cardaioli P, Ronco F, Giordan M, Aryal MR, Pandit AA, Jalota L, Kantharajpur S, Hakim FA, Lee HR. Amplatzer PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta-analysis of randomised trials. *Heart Lung Circ* 2014; 23: 303-308 [PMID: 24495944 DOI: 10.1016/j.hlc.2013.12.003]

16. Capodanno D, Milazzo G, Vitale L, Di Stefano D, Di Salvo M, Grasso C, Tamburino C. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. *EuroIntervention* 2014; 9: 1342-1349 [PMID: 24240356 DOI: 10.4244/EIJV9I9A225]

17. Rigatelli G, Dell’avvocata F, Vassiliev D, Daggubati R, Buch, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Teyyeh I, Khuder S, Eltahawy EA. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a meta-analysis of randomized clinical trials. *BMC Cardiovasc Disord* 2013; 13: 116 [PMID: 24330204 DOI: 10.1186/1471-2261-13-116]

18. Rigatelli G, Dell’avvocata F, Vassiliev D, Daggubati R, Buch, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Teyyeh I, Khuder S, Eltahawy EA. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a meta-analysis of randomized clinical trials. *BMC Cardiovasc Disord* 2013; 13: 116 [PMID: 24330204 DOI: 10.1186/1471-2261-13-116]

19. Pristipino C, Anzola GP, Ballerini L, Bartorelli A, Cecconi M, Chessa M, Doni T, Gaspardone A, Neri G, Onorato E, Palareti G, Rakar S, Rigatelli G, Santoro G, Toni D, Ussia GP, Violini R. Management of patients with patent foramen ovale and cryptogenic stroke: a collaborative, multidisciplinary, position paper: executive summary. *Catheter Cardiovasc Interv* 2013; 82: 122-129 [PMID: 23788390 DOI: 10.1002/ccd.24693]

20. Xu WH, Xin YQ, Yan ZR, Jiang JD, Gao S. Cardiac right-to-left shunt subtypes in Chinese patients with cryptogenic strokes: a multicenter case-control study. *Eur J Neurol* 2014; 21: 525-528 [PMID: 24444328 DOI: 10.1111/ene.12351]

P-Reviewer: Anan R, Chu D, Jankowski K, Kasai T
S-Editor: Tian YL
L-Editor: A
E-Editor: Zhang DN
